Tag

Outcomes Based Agreements

All articles tagged with #outcomes based agreements

"Expanding Access: Medicaid's Outcomes-Based Agreements for Sickle Cell Gene Therapies"
healthcare1 year ago

"Expanding Access: Medicaid's Outcomes-Based Agreements for Sickle Cell Gene Therapies"

The Centers for Medicare and Medicaid Services (CMS) will implement a program to reimburse expensive gene therapies for sickle cell disease based on patient outcomes, marking a significant shift in financing high-cost treatments. Starting next year, Medicaid programs will test outcomes-based agreements to pay for two FDA-approved gene therapies, with list prices of $2.2 million and $3.1 million, respectively.

"Advancements in Sickle Cell Gene Therapies Offer Hope for Patients"
healthcare2 years ago

"Advancements in Sickle Cell Gene Therapies Offer Hope for Patients"

The U.S. government plans to implement an "access model" to help state Medicaid programs afford new gene therapies for sickle cell disease, which come with multimillion-dollar price tags. The Centers for Medicare and Medicaid Services will pursue outcomes-based agreements with drug manufacturers to negotiate pricing and rebates on behalf of participating states, starting in January 2025. This move aims to alleviate concerns over the financial burden of these curative treatments on Medicaid programs, which many people with sickle cell disease rely on for health care coverage.